Search 

ORIGIMM is a young, ambitious Austrian biotech company striving to become a market leader in the treatment of acute and chronic infectious diseases, and dermatological conditions associated with various pathogens.

ORIGIMM is developing the worldwide first therapeutic vaccine for treatment of acne vulgaris; the disease with enormous market potential, afflicting 85% of teenagers and more than 20% of adults below 40 years of age.

Using its proprietary ProVaDis® technology platform ORIGIMM overcomes the challenges in vaccine and immune therapy development by early focus on protective efficacy of antigens in the context of human disease. This translates into a rapid selection of best, most protective candidates with a significantly improved success in clinical trials. ProVaDis platform enables ORIGIMM to rapidly build its product portfolio in many other lucrative areas.

RECARDIO is a virtual, private, clinical stage life science company founded in 2011 focusing on drug based regenerative therapeutic modalities for the treatment of cardiovascular diseases.

The company started product development mid-stage by taking advantage of >$100m of previously invested capital in the licensed lead compound, Dutogliptin. Safety has been established in more than 1000 subjects and all non-clinical studies have been completed to the highest standards, including 2 year carcinogenicity, resulting in a de-risked clinical development program from the safety perspective and overall reduction in total program costs.

 After completion of limited preclinical studies clinical trials will commence in early 2015 in patients with acute myocardial infarction.

After establishing proof-of-principle in vivo and completion of the preclinical development, it has entered clinical stage and is developing multiple therapeutic leads as the future regenerative medication for patients with various cardiovascular diseases, with the potential of improving their cardiac function, quality of life and survival.